Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epstein bullish on Gilenya after strong Q2

This article was originally published in Scrip

Executive Summary

David Epstein, head of Novartis Pharmaceuticals, urged analysts to take a rosier view of the ex-US prospects for its multiple sclerosis drug Gilenya (fingolimod) after the product turned in healthy growth in the second quarter. "I believe people still have expectations which are too low for this very, very important brand for us," he declared, pointing out that the in the first half of 2012 ex-US sales grew by 94% compared with the end of 2011.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel